Suchergebnisse - "Ophthalmology (Rochester, Minn.)"

Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis von Teo, Zhen Ling, Tham, Yih-Chung, Yan Yu, Marco Chak, Chee, Miao Li, Rim, Tyler Hyungtaek, Cheung, Ning, Bikbov, Mukharram M, Wang, Ya Xing, Tang, Yating, Lu, Yi, Hin Wong, Ian Yat, Wei Ting, Daniel Shu, Wei Tan, Gavin Siew, Jonas, Jost B, Sabanayagam, Charumathi, Wong, Tien Yin, Cheng, Ching-Yu

“… To provide updated estimates on the global prevalence and number of people with diabetic retinopathy (DR) through 2045. The International diabetes federation …”
Weitere Angaben

International Classification of Retinopathy of Prematurity, Third Edition von Chiang, Michael F, Quinn, Graham E, Fielder, Alistair R, Ostmo, Susan R, Paul Chan, R V, Berrocal, Audina, Binenbaum, Gil, Blair, Michael, Peter Campbell, J, Capone, Jr, Antonio, Chen, Yi, Dai, Shuan, Ells, Anna, Fleck, Brian W, Good, William V, Elizabeth Hartnett, M, Holmstrom, Gerd, Kusaka, Shunji, Kychenthal, Andrés, Lepore, Domenico, Lorenz, Birgit, Martinez-Castellanos, Maria Ana, Özdek, Şengül, Ademola-Popoola, Dupe, Reynolds, James D, Shah, Parag K, Shapiro, Michael, Stahl, Andreas, Toth, Cynthia, Vinekar, Anand, Visser, Linda, Wallace, David K, Wu, Wei-Chi, Zhao, Peiquan, Zin, Andrea

“… The International Classification of Retinopathy of Prematurity is a consensus statement that creates a standard nomenclature for classification of retinopathy …”
Weitere Angaben

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results von Martin, Daniel F, Maguire, Maureen G, Fine, Stuart L, Ying, Gui-Shuang, Jaffe, Glenn J, Grunwald, Juan E, Toth, Cynthia, Redford, Maryann, Ferris, 3rd, Frederick L

“… To describe effects of ranibizumab and bevacizumab when administered monthly or as needed for 2 years and to describe the impact of switching to as-needed …”
Weitere Angaben

Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group von Spaide, Richard F, Jaffe, Glenn J, Sarraf, David, Freund, K Bailey, Sadda, Srinivas R, Staurenghi, Giovanni, Waheed, Nadia K, Chakravarthy, Usha, Rosenfeld, Philip J, Holz, Frank G, Souied, Eric H, Cohen, Salomon Y, Querques, Giuseppe, Ohno-Matsui, Kyoko, Boyer, David, Gaudric, Alain, Blodi, Barbara, Baumal, Caroline R, Li, Xiaoxin, Coscas, Gabriel J, Brucker, Alexander, Singerman, Lawrence, Luthert, Phil, Schmitz-Valckenberg, Steffen, Schmidt-Erfurth, Ursula, Grossniklaus, Hans E, Wilson, David J, Guymer, Robyn, Yannuzzi, Lawrence A, Chew, Emily Y, Csaky, Karl, Monés, Jordi M, Pauleikhoff, Daniel, Tadayoni, Ramin, Fujimoto, James

“… To establish a process to evaluate and standardize a state-of-the-art nomenclature for reporting neovascular age-related macular degeneration (AMD) data …”
Weitere Angaben

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration von Dugel, Pravin U, Koh, Adrian, Ogura, Yuichiro, Jaffe, Glenn J, Schmidt-Erfurth, Ursula, Brown, David M, Gomes, Andre V, Warburton, James, Weichselberger, Andreas, Holz, Frank G

“… Two similarly designed phase 3 trials (HAWK and HARRIER) compared brolucizumab, a single-chain antibody fragment that inhibits vascular endothelial growth …”
Weitere Angaben

C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial von Jaffe, Glenn J, Westby, Keith, Csaky, Karl G, Monés, Jordi, Pearlman, Joel A, Patel, Sunil S, Joondeph, Brian C, Randolph, John, Masonson, Harvey, Rezaei, Kourous A

“… The complement pathway may play a key role in the pathogenesis of age-related macular degeneration (AMD). The safety and efficacy of avacincaptad pegol …”
Weitere Angaben

Effect of Repeated Low-Level Red-Light Therapy for Myopia Control in Children: A Multicenter Randomized Controlled Trial von Jiang, Yu, Zhu, Zhuoting, Tan, Xingping, Kong, Xiangbin, Zhong, Hui, Zhang, Jian, Xiong, Ruilin, Yuan, Yixiong, Zeng, Junwen, Morgan, Ian G, He, Mingguang

“… To assess the efficacy and safety of repeated low-level red-light (RLRL) therapy in myopia control in children. Multicenter, randomized, parallel-group, …”
Weitere Angaben

Diabetic Retinopathy Preferred Practice Pattern von Flaxel, Christina J, Adelman, Ron A, Bailey, Steven T, Fawzi, Amani, Lim, Jennifer I, Vemulakonda, G Atma, Ying, Gui-Shuang

Weitere Angaben

Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER von Monés, Jordi, Srivastava, Sunil K, Jaffe, Glenn J, Tadayoni, Ramin, Albini, Thomas A, Kaiser, Peter K, Holz, Frank G, Korobelnik, Jean-Francois, Kim, Ivana K, Pruente, Christian, Murray, Timothy G, Heier, Jeffrey S

“… An independent Safety Review Committee (SRC), supported by Novartis Pharma AG, analyzed investigator-reported cases of intraocular inflammation (IOI), …”
Weitere Angaben

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial von Liao, David S, Grossi, Federico V, El Mehdi, Delphine, Gerber, Monica R, Brown, David M, Heier, Jeffrey S, Wykoff, Charles C, Singerman, Lawrence J, Abraham, Prema, Grassmann, Felix, Nuernberg, Peter, Weber, Bernhard H F, Deschatelets, Pascal, Kim, Robert Y, Chung, Carol Y, Ribeiro, Ramiro M, Hamdani, Mohamed, Rosenfeld, Philip J, Boyer, David S, Slakter, Jason S, Francois, Cedric G

“… Geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), is a major cause of blindness. Even while central visual acuity remains …”
Weitere Angaben

Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings von Wong, Tien Y, Sun, Jennifer, Kawasaki, Ryo, Ruamviboonsuk, Paisan, Gupta, Neeru, Lansingh, Van Charles, Maia, Mauricio, Mathenge, Wanjiku, Moreker, Sunil, Muqit, Mahi M K, Resnikoff, Serge, Verdaguer, Juan, Zhao, Peiquan, Ferris, Frederick, Aiello, Lloyd P, Taylor, Hugh R

“… Diabetes mellitus (DM) is a global epidemic and affects populations in both developing and developed countries, with differing health care and resource levels …”
Weitere Angaben

Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients von Seah, Ivan Yu Jun, Anderson, Danielle E, Kang, Adrian Eng Zheng, Wang, Linfa, Rao, Pooja, Young, Barnaby Edward, Lye, David Chien, Agrawal, Rupesh

Weitere Angaben

Primary Open-Angle Glaucoma Preferred Practice Pattern von Gedde, Steven J, Vinod, Kateki, Wright, Martha M, Muir, Kelly W, Lind, John T, Chen, Philip P, Li, Tianjing, Mansberger, Steven L

Weitere Angaben

Efficacy of a Deep Learning System for Detecting Glaucomatous Optic Neuropathy Based on Color Fundus Photographs von Li, Zhixi, He, Yifan, Keel, Stuart, Meng, Wei, Chang, Robert T, He, Mingguang

“… To assess the performance of a deep learning algorithm for detecting referable glaucomatous optic neuropathy (GON) based on color fundus photographs. A deep …”
Weitere Angaben

Time Outdoors in Reducing Myopia: A School-Based Cluster Randomized Trial with Objective Monitoring of Outdoor Time and Light Intensity von He, Xiangui, Sankaridurg, Padmaja, Wang, Jingjing, Chen, Jun, Naduvilath, Thomas, He, Mingguang, Zhu, Zhuoting, Li, Wayne, Morgan, Ian G, Xiong, Shuyu, Zhu, Jianfeng, Zou, Haidong, Rose, Kathryn A, Zhang, Bo, Weng, Rebecca, Resnikoff, Serge, Xu, Xun

“… To evaluate the efficacy of time outdoors per school day over 2 years on myopia onset and shift.PURPOSETo evaluate the efficacy of time outdoors per school day …”
Weitere Angaben

Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050 von Holden, Brien A, Fricke, Timothy R, Wilson, David A, Jong, Monica, Naidoo, Kovin S, Sankaridurg, Padmaja, Wong, Tien Y, Naduvilath, Thomas J, Resnikoff, Serge

“… Myopia is a common cause of vision loss, with uncorrected myopia the leading cause of distance vision impairment globally. Individual studies show variations …”
Weitere Angaben

Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3 von Sadda, Srinivas R, Guymer, Robyn, Holz, Frank G, Schmitz-Valckenberg, Steffen, Curcio, Christine A, Bird, Alan C, Blodi, Barbara A, Bottoni, Ferdinando, Chakravarthy, Usha, Chew, Emily Y, Csaky, Karl, Danis, Ronald P, Fleckenstein, Monika, Freund, K Bailey, Grunwald, Juan, Hoyng, Carel B, Jaffe, Glenn J, Liakopoulos, Sandra, Monés, Jordi M, Pauleikhoff, Daniel, Rosenfeld, Philip J, Sarraf, David, Spaide, Richard F, Tadayoni, Ramin, Tufail, Adnan, Wolf, Sebastian, Staurenghi, Giovanni

“… To develop consensus terminology and criteria for defining atrophy based on OCT findings in the setting of age-related macular degeneration (AMD). Consensus …”
Weitere Angaben

Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control von Yam, Jason C, Jiang, Yuning, Tang, Shu Min, Law, Antony K P, Chan, Joyce J, Wong, Emily, Ko, Simon T, Young, Alvin L, Tham, Clement C, Chen, Li Jia, Pang, Chi Pui

“… Low-concentration atropine is an emerging therapy for myopia progression, but its efficacy and optimal concentration remain uncertain. Our study aimed to …”
Weitere Angaben

The Risks and Benefits of Myopia Control von Bullimore, Mark A, Ritchey, Eric R, Shah, Sunil, Leveziel, Nicolas, Bourne, Rupert R A, Flitcroft, D Ian

“… The prevalence of myopia is increasing around the world, stimulating interest in methods to slow its progression. The primary justification for slowing myopia …”
Weitere Angaben

HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration von Dugel, Pravin U, Singh, Rishi P, Koh, Adrian, Ogura, Yuichiro, Weissgerber, Georges, Gedif, Kinfemichael, Jaffe, Glenn J, Tadayoni, Ramin, Schmidt-Erfurth, Ursula, Holz, Frank G

“… To report the 96-week outcomes from HAWK and HARRIER. Phase 3, prospective, randomized, double-masked, multicenter studies comparing efficacy and safety of …”
Weitere Angaben